Form D · Biotechnology
Objective Biotechnology, Inc.
Minneapolis, MN · CIK 0002045193
Offering snapshot reported Nov 26, 2024 · SEC filing
- Reported sold
- $715K Offering amount: $1M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 20, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 26, 2024 | Initial | $714,984 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-530516
Source: Form D, filed Nov 26, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Alegria | Director, Executive |
| Daryl Gohl | Director, Executive |
| James Grabau | Executive |
| Amey Joshi | Director, Executive |
| Suhasa Kodandaramaiah | Director, Executive |
| Daniel Surinach | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
126 N. Third Street, Suite 540
Minneapolis, MN, 55401
Minneapolis, MN, 55401